natgillin/translations-raw huggingface dataset:
Teicoplanin trough serum concentrations should be monitored at steady state after completion of the loading dose regimen in order to ensure that a minimum trough serum concentration has been reached: 
Najnižjo koncentracijo teikoplanina v serumu je treba kontrolirati v stanju dinamičnega ravnovesja po dokončanju sheme polnilnih odmerkov in tako preveriti, da je bila dosežena minimalna najnižja koncentracija v serumu:
These include aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, and ethacrynic acid (see section 4.4). 
Med takšna spadajo aminoglikozidi, kolistin, amfotericin B, ciklosporin, cisplatin, furosemid in etakrinska kislina (glejte poglavje 4.4).
There is no information on the excretion of teicoplanin in animal milk. 
Informacij o izločanju teikoplanina v mleko pri živalih ni.
Gram-positive anaerobes except Clostridium difficile PK/PD (Non-species related) breakpoints c,d 
Grampozitivni anaerobi razen Clostridium difficile FK/FD mejne vrednosti (nepovezane z vrsto) c,d
Cross-resistance between teicoplanin and the glycoprotein vancomycin may occur. 
Pojavi se lahko navzkrižna odpornost med teikoplaninom in glikoproteinom vankomicinom.
• difficulty in breathing or wheezing (bronchospasm) 
• težko dihanje ali piskajoče dihanje (bronhospazem)
Adults and children (12 years and over) with no kidney problems Skin and soft tissue, lung and urinary tract infections 
Odrasli in otroci (stari 12 let ali več), ki nimajo težav z ledvicami Okužbe kože in mehkih tkiv, pljuč in sečil
In the elderly population the teicoplanin pharmacokinetics is not modified unless in case of renal impairment. 
• Starejši bolniki: V starejši populaciji se farmakokinetika teikoplanina ne spremeni razen v primeru okvare ledvic.
Studies to investigate the potential to cause ototoxicity in the guinea-pig indicate that a mild impairment of cochlear and vestibular function is possible, in the absence of morphological damage. 
Študije za preučitev možnosti za ototoksičnost pri morskih prašičkih kažejo, da se lahko pojavi blaga okvara kohlearnega in vestibularnega delovanja, in sicer v odsotnosti morfološke okvare.
- Infective endocarditis 
- Infekcijski endokarditis
Teicoplanin has a low total clearance in the range of 10 to 14 mL/h/kg and a renal clearance in the range of 8 to 12 mL/h/kg indicating that teicoplanin is mainly excreted by renal mechanisms. 
Teikoplanin ima nizek celotni očistek v razponu od 10 do 14 ml/h/kg in ledvični očistek v razponu od 8 do 12 ml/h/kg; to kaže, da se teikoplanin v glavnem izloči z ledvičnimi mehanizmi.
In rare cases (even at the first dose), red man syndrome (a complex of symptoms including pruritus, urticaria, erythema, angioneurotic oedema, tachycardia, hypotension, dyspnoea) has been observed. 
V redkih primerih so (celo že po prvem odmerku) opažali sindrom rdečega moža (skupek simptomov, ki vključuje srbenje, urtikarijo, eritem, angionevrotični edem, tahikardijo, hipotenzijo, dispnejo).
Patients in continuous ambulatory peritoneal dialysis (CAPD) After a single intravenous loading dose of 6 mg/kg bodyweight, 20 mg/L is administered in the bag of the dialysis solution in the first week, 20 mg/L in different bags the second week and then 20 mg/L in the overnight bag in the third week. 
Bolniki na kontinuirani ambulantni peritonealni dializi (CAPD) Po enkratnem intravenskem polnilnem odmerku 6 mg/kg telesne mase je treba dati 20 mg/l v vsako vrečko dializne tekočine prvi teden, 20 mg/l v vsako drugo vrečko drugi teden in 20 mg/l v vrečko za čez noč tretji teden.
Targocid is used in adults and children (including newborn babies) to treat bacterial infections of: the skin and underneath the skin - sometimes called ‘soft tissue' the bones and joints the lung the urinary tract the heart - sometimes called ‘endocarditis' the abdominal wall - peritonitis the blood, when caused by any of the conditions listed above 
Zdravilo Targocid se uporablja pri odraslih in otrocih (vključno z novorojenčki) za zdravljenje bakterijskih okužb: kože in podkožja - to včasih imenujemo "mehka tkiva", kosti in sklepov, pljuč, sečil, srca - to včasih imenujemo "endokarditis", trebušne stene - peritonitis, krvi, če je to posledica katere koli od zgoraj omenjenih bolezni.
• you have a flushing of your upper part of your boby (red man syndrome) 
• če se vam pojavlja zardevanje zgornjega dela telesa ("sindrom rdečega moža"),
• Renal impairment: 
• Okvara ledvic:
equisimilis a (Group C & G streptococci) 
equisimilis a (Streptokoki skupin C in G)
Since data on safety are limited, patients should be carefully monitored for adverse reactions when teicoplanin doses of 12mg/kg body weight twice a day are administered. 
Ker je podatkov malo, je treba bolnike skrbno nadzirati glede neželenih učinkov, če je teikoplanin uporabljen v odmerkih 12 mg/kg telesne mase dvakrat na dan.
0.18% sodium chloride and 4% glucose solution 0.45% sodium chloride and 5% glucose solution Peritoneal dialysis solution containing 1.36% or 3.86% glucose solution. 
10 % glukoza za injekcije raztopina 0,18 % natrijevega klorida in 4 % glukoze raztopina 0,45 % natrijevega klorida in 5 % glukoze raztopina za peritonealno dializo, ki vsebuje 1,36 % ali 3,86 % raztopine glukoze.
Measured by FPIA 
Merjena s FPIA
Studies in animals reproduction have not shown evidence of fertility problems. 
Študije sposobnosti razmnoževanja pri živalih niso pokazale težav s plodnostjo.
Teicoplanin and aminoglycoside are incompatible when mixed directly and must not be mixed before injection. 
Teikoplanin in aminoglikozidi ob neposrednem mešanju niso združljivi, zato se jih pred injiciranjem ne sme mešati.
Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. 
Teikoplanin zavira rast občutljivih organizmov tako, da ovira biosintezo celične stene na drugih mestih kot betalaktami.
Neonates and infants up to the age of 2 months: 
Novorojenčki in dojenčki do starosti 2 mesecev:
A number of vancomycin-resistant enterococci are sensitive to teicoplanin (Van-B phenotype). 
Številni enterokoki, odporni proti vankomicinu, so občutljivi za teikoplanin (fenotip Van-B).
>15 mg/L once a week 
> 15 mg/l1 enkrat na teden
It is unknown whether teicoplanin is excreted in human milk. 
Ni znano, ali se teikoplanin pri človeku izloča v materino mleko.
• Gently roll the vial between the hands until the powder is completely dissolved. 
• Vialo nežno vrtite med dlanmi, dokler ni prašek povsem raztopljen.
As with other antibiotics, the use of teicoplanin, especially if prolonged, may result in overgrowth of nonsusceptible organisms. 
Tako kot med uporabo drugih antibiotikov se lahko tudi med uporabo teikoplanina razrastejo neobčutljivi organizmi, zlasti če je njegova uporaba dolgotrajna.
Patients who develop signs and symptoms of impaired hearing or disorders of the inner ear during treatment with teicoplanin should be carefully evaluated and monitored, especially in case of prolonged treatment and in patients with renal insufficiency. 
Bolnike, ki se jim med zdravljenjem s teikoplaninom pojavijo znaki ali simptomi okvare sluha ali motenj notranjega ušesa, je treba skrbno oceniti in kontrolirati, zlasti v primeru dolgotrajnega zdravljenja in pri bolnikih z insuficienco ledvic.
• The other ingredients are sodium chloride and sodium hydroxide. 
• Drugi sestavini sta natrijev klorid in natrijev hidroksid.
Teicoplanin must be administered with caution in patients with known hypersensitivity to vancomycin, as crossed hypersensitivity reactions, including fatal anaphylactic shock, may occur. 
Teikoplanin je treba previdno uporabljati pri bolnikih z znano preobčutljivostjo za vankomicin, kajti pojavijo se lahko navzkrižne preobčutljivostne reakcije, vključno z anafilaktičnim šokom s smrtnim izidom.
• sudden life-threatening allergic reaction - the signs may include: difficulty in breathing or wheezing, swelling, rash, itching, fever, chills 
• nenadna življenje ogrožujoča alergijska reakcija - med znaki so lahko: težave z dihanjem ali piskajoče dihanje, oteklost, izpuščaj, srbenje, zvišana telesna temperatura, mrzlica
Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues. 
Sintezo peptidoglikanov blokira s specifično vezavo na D-alanil-D-alaninske skupine.
Children (from 2 months to 12 years) 
Otroci (od 2 mesecev do 2 let)
Targocid and associated names (see Annex I) is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis. 
Zdravilo Targocid in povezana imena (glejte Prilogo I) je indicirano tudi kot alternativno peroralno zdravljenje driske in kolitisa, povezanih z okužbo s Clostridium difficile.
Water for injections is packaged in Type I, colourless glass ampoule. 
Voda za injekcije je pakirana v ampuli iz brezbarvnega stekla tipa I.
If you are pregnant, think that you might be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before being given this medicine. 
Če ste noseči, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite to zdravilo.
In particular, tell your doctor, pharmacist or nurse if you are taking the following medicines: 
Še zlasti morate svojemu zdravniku, medicinski sestri ali farmacevtu povedati, če jemljete katero od naslednjih zdravil:
Volume containing nominal teicoplanin dose (extracted by 5 mL syringe and 23 G needle) 
Količina, ki vsebuje nominalen odmerek teikoplanina (izvlečeno s 5-ml brizgo in iglo 23 G)
Rare (may affect up to 1 in 1000 people) • flushing of the upper body 
Redki (pojavijo se lahko pri največ 1 od 1000 oseb) • zardevanje zgornjega dela telesa
Disposal Any unused medicine or waste material should be disposed of in accordance with local requirements. 
Odstranjevanje Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
Uncommon (≥1/1,000 to 
Občasni (≥ 1/1.000 do <
Severe bullous reactions 
Huda bulozne reakcije
Anaphylactic shock (see section 4.4) 
anafilaktični šok (glejte poglavje 4.4)
Hypersensitivity to teicoplanin or to any of the excipients listed in section 6. 
Preobčutljivost za teikoplanin ali katero koli pomožno snov, navedeno v poglavju 6.
Adverse reactions should be monitored when teicoplanin doses of 12 mg/kg body weight twice a day are administered (see section 4.4). 
Kontroliranje glede neželenih učinkov je potrebno, če je teikoplanin uporabljen v odmerkih 12 mg/kg telesne mase dvakrat na dan (glejte poglavje 4.4).
Elderly population No dose adjustment is required, unless there is renal impairment (see below). 
Starejša populacija Odmerka ni treba prilagoditi, če bolnik nima okvare ledvic (glejte spodaj).
Targocid can be administered in the following infusion solutions: sodium chloride 9 mg/mL (0.9%) solution Ringer solution 
Zdravilo Targocid se lahko uporabi v naslednjih raztopinah za infundiranje: raztopina natrijevega klorida 9 mg/ml (0,9 %) Ringerjeva raztopina
As teicoplanin is eliminated by renal route, teicoplanin elimination decreases according to the degree of renal impairment. 
Ker se teikoplanin izloča skozi ledvice, se njegovo izločanje zmanjšuje v skladu s stopnjo okvare ledvic.
Summary of product characteristics, labelling and package leaflet 
Povzetek glavnih značilnosti zdravila, Označevanje in navodilo za uporabo
Preparation of the diluted solution before infusion: 
Priprava razredčene raztopine pred infundiranjem:
Stopping or slowing the infusion may result in cessation of these reactions. 
Te reakcije lahko izginejo po prekinitvi ali upočasnitvi infundiranja.
Linearity Teicoplanin exhibited linear pharmacokinetics at dose range of 2 to 25 mg/kg. 
Linearnost Farmakokinetika teikoplanina je bila v razponu odmerkov od 2 do 25 mg/kg linearna.
• The other ingredients are sodium chloride and sodium hydroxide in the powder; and water for injections in the solvent. 
• Druge sestavine so: natrijev klorid in natrijev hidroksid v prašku in voda za injekcije v vehiklu.
To treat certain infections, the solution may be taken by mouth (oral use). 
Za zdravljenje določenih okužb je mogoče raztopino uporabljati peroralno (jo zaužiti).
Bone and joint infections, and heart infections 
Okužbe kosti in sklepov ter okužbe srca
Do not use this medicine after the expiry date which is stated on the carton and label of the vial after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki poleg oznake EXP. Datum izteka roka uporabnosti se nanaša na zadnji dan navedenega meseca.
• you are taking or may take other medicines that may affect your nervous system, kidneys or hearing. 
• če jemljete ali bi se lahko zgodilo, da bi jemali zdravila, ki vplivajo na živčevje, ledvice ali sluh.
The responsible enzymes are a newly synthesised D-lactate dehydrogenase or ligase. 
Odgovorni encim je novosintetizirana D-laktat-dehidrogenaza ali ligaza.
Manufacturer [To be completed nationally] 
Izdelovalec [Izpolni država članica]
• lack of white blood cells - the signs may include: fever, severe chills, sore throat or mouth ulcers (agranulocytosis) 
• pomanjkanje belih krvnih celic - med znaki so lahko: zvišana telesna temperatura, huda mrzlica, vnetje žrela ali razjede v ustih (agranulocitoza)
The recommended dose is 
Priporočeni odmerek
The reconstituted solutions will contain 100 mg of teicoplanin in 1.5 mL, 200 mg in 3.0 mL and 400 mg in 3.0 mL. 
Pripravljena raztopina bo vsebovala 100 mg teikoplanina v 1,5 ml, 200 mg v 3,0 ml in 400 mg v 3,0 ml.
Teicoplanin should be used with care in conjunction with or sequentially with other medicinal products with known nephrotoxic or ototoxic potential. 
Teikoplanin je treba previdno uporabljati skupaj ali v zaporedju z drugimi zdravili, ki so lahko nefrotoksična ali ototoksična.
The injection will be given either as a bolus over 3 to 5 minutes or as a 30-minutes infusion. 
Zdravilo se injicira ali kot bolus v 3 do 5 minutah ali kot 30-minutno infuzijo.
In embryofetal development studies, no malformations were observed following subcutaneous administration of up to 200 mg/kg/day in the rat and intramuscular administration up to 15 mg/kg/day in the rabbit. 
V študijah embriofetalnega razvoja niso opažali malformacij po subkutani uporabi odmerkov do 200 mg/kg/dan pri podganah in po intramuskularni uporabi odmerkov do 15 mg/kg/dan pri kuncih.
Preparation of the diluted solution before infusion Targocid can be administered in the following infusion solutions: 
Priprava razredčene raztopine pred infundiranjem Zdravilo Targocid je mogoče aplicirati z naslednjimi raztopinami za infundiranje:
Powder for solution for injection/infusion or oral solution also contains: sodium chloride, sodium hydroxide (for pH adjustment). 
Prašek za raztopino za injiciranje ali infundiranje ali za peroralno raztopino vsebuje tudi: natrijev klorid, natrijev hidroksid (za prilagoditev pH).
Teicoplanin has a limited spectrum of antibacterial activity (Gram positive). 
Teikoplanin ima omejen spekter protibakterijskega delovanja (Grampozitiven).
In pleural fluid and subcutaneous fat tissue the tissue/serum ratios are comprised between 0.2 and 0.5. 
V plevralni tekočini in podkožnem maščevju je razmerje tkivo/serum med 0,2 in 0,5.
Teicoplanin should not be administered by intraventricular use. 
Teikoplanina se ne sme uporabljati intraventrikularno.
Teicoplanin has a limited spectrum of antibacterial activity (Gram-positive). 
Teikoplanin ima omejen spekter protibakterijskega delovanja (grampozitivni).
Teicoplanin is not removed by haemodialysis and only slowly by peritoneal dialysis. 
Teikoplanin se s hemodializo ne odstrani, s peritonealno dializo pa se odstrani le počasi.
Subcutaneous administration of teicoplanin at up to 40 mg/kg/day did not affect male and female fertility in the rat. 
Subkutana uporaba teikoplanina v odmerkih do 40 mg/kg/dan pri podganah ni vplivala na plodnost samcev in samic.
During treatment you may have tests to check your kidneys and/or your hearing. 
Med zdravljenjem boste morda opravili preiskave za kontrolo ledvic, sluha ali obojega.
The reconstituted solution may be injected directly or alternatively further diluted. 
Pripravljeno raztopino je mogoče injicirati neposredno, mogoče pa jo je še dodatno redčiti.
Since teicoplanin is mainly excreted by the kidney, the dose of teicoplanin must be adapted in patients with renal impairment (see section 4.2). 
Ker se teikoplanin v glavnem izloča skozi ledvice, zato je treba bolnikom z okvaro ledvic odmerek teikoplanina prilagoditi (glejte poglavje 4.2).
• Slowly inject the entire content of the supplied solvent into the powder vial. 
• Počasi injicirajte celotno količino priloženega vehikla v vialo s praškom.
This effect was not reported at 50 mg/kg/day A peri and postnatal study in rats showed no effects on the fertility of the F1 generation or on the survival and development of the F2 generation following subcutaneous administration of up to 40 mg/kg/day. 
Peri- in postnatalna študija pri podganah ni pokazala vpliva na plodnost generacije F1 ali na preživetje in razvoj generacije F2 po subkutani uporabi odmerkov do 40 mg/kg/dan.
Therefore, this SmPC, labelling and package leaflet may not necessarily represent the current text. 
Zato ta Povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo ni nujno zadnje veljavno besedilo.
• In mild and moderate renal insufficiency (creatinine clearance 30-80 mL/min): maintenance dose should be halved, either by administering the dose every two days or by administering half of this dose once a day. 
• Pri blagi do zmerni insuficienci ledvic (očistek kreatinina 30-80 ml/min): vzdrževalni odmerek je treba prepoloviti, bodisi z uporabo odmerka na dva dni bodisi z uporabo pol tega odmerka enkrat na dan.
Teicoplanin distributed mainly in lung, myocardium and bone tissues with tissue/serum ratios superior to 1. 
Teikoplanin se porazdeli predvsem v pljuča, miokard in kostno tkivo; razmerje tkivo/serum presega 1.
The solvent is a clear and colourless solution. 
Vehikel je bistra in brezbarvna raztopina.
• complicated skin and soft tissue infections, 
• zapletene okužbe kože in mehkih tkiv,
• 0.18% sodium chloride and 4% glucose solution 
• raztopina 0,18 % natrijevega klorida in 4 % glukoze
• feeling dizzy or headache 
• omotica ali glavobol
• In severe renal insufficiency (creatinine clearance less than 30 mL/min) and in haemodialysed patients: dose should be one-third the usual dose, either by administering the initial unit dose every third day or by administering one-third of this dose once a day. 
• Pri hudi insuficienci ledvic (očistek kreatinina manj kot 30 ml/min) in bolniki na hemodializi: odmerek mora biti eno tretjino običajnega, bodisi z uporabo uvodnega posameznega odmerka vsak tretji dan bodisi z uporabo ene tretjine tega odmerka enkrat na dan. Hemodializa ne odstrani teikoplanina.
Teicoplanin does not readily penetrate into the cerebrospinal fluid (CSF). 
Teikoplanin težko prodre v cerebrospinalno tekočino.
Susceptibility 
Občutljivost
Resistant 
Odporni
They will decide whether or not you can keep breast-feeding, while you are given Targocid. 
Presodil bo, ali lahko med prejemanjem zdravila Targocid nadaljujete z dojenjem.
The intravenous injection may be administered either as a bolus over 3 to 5 minutes or as a 30-minute infusion. 
Intravensko injekcijo je mogoče dati v bolusu v 3 do 5 minutah ali v 30-minutni infuziji.
Each vial contains either 100 mg, 200 mg or 400 mg teicoplanin. 
Ena viala vsebuje 100 mg, 200 mg ali 400 mg teikoplanina.
Patients receiving teicoplanin in conjunction with or sequentially with other medicinal products with known neurotoxic/ototoxic potential (aminoglycosides, ciclosporin, cisplatin, furosemide and ethacrynic acid) should be carefully monitored and the benefit of teicoplanin evaluated if hearing deteriorates. 
Bolnike, ki teikoplanin prejemajo skupaj ali v zaporedju z drugimi potencialno nevrotoksičnimi/ototoksičnimi zdravili (aminoglikozidi, ciklosporinom, cisplatinom, furosemidom ali etakrinsko kislino), je treba skrbno kontrolirati; če se jim sluh poslabša, je treba oceniti korist zdravljenja s teikoplaninom.
• 0.45% sodium chloride and 5% glucose solution 
• raztopina 0,45 % natrijevega klorida in 5 % glukoze
Diarrhoea, vomiting, nausea 
Bolezni prebavil driska, bruhanje, navzea
Stevens-Johnson syndrome, erythema multiforme, angioedema, dermatitis exfoliative, urticaria (see section 
toksična epidermalnanekroliza, Stevens-Johnsonov sindrom, multiformni eritem, angioedem, eksfoliativni dermatitis, urtikarija (glejte poglavje 4.4)
Red man syndrome (e.g. Flushing of the upper part of the body) (see section 4.4). 
Bolezni kože in podkožja izpuščaj, eritem, srbenje sindrom rdečega moža (npr. zardevanje zgornjega dela telesa) (glejte poglavje 4.4).
After six daily intramuscular administrations of 200 mg the mean (SD) maximum teicoplanin concentration (Cmax) amounts to 12.1 (0.9) mg/L and occurs at 2 hours after administration. 
Po šestih dneh intramuskularne uporabe 200 mg je povprečna (standardni odklon) največja koncentracija teikoplanina (Cmax) 12,1 (0,9) mg/l in je dosežena 2 uri po dajanju zdravila.
Superinfection (overgrowth of non-susceptible organisms) 
Infekcijske in parazitske bolezni absces superinfekcija (razrast neobčutljivih organizmov)
Patients with renal insufficiency, and/or in those receiving teicoplanin in conjunction with or sequentially with other medicinal products with known nephrotoxic potential (aminoglycosides, colistin, amphotericin B, ciclosporin, and cisplatin) should be carefully monitored, and should include auditory tests. 
Bolnike z insuficienco ledvic in/ali bolnike, ki teikoplanin prejemajo skupaj ali v zaporedju z drugimi potencialno nefrotoksičnimi zdravili (aminoglikozidi, kolistinom, amfotericinom B, ciklosporinom, cisplatinom), je treba skrbno kontrolirati; spremljanje mora vključevati preiskave sluha.
• hospital acquired pneumonia, 
• v bolnišnici dobljena pljučnica,
Primary packaging: 
Priprava raztopine:
• raised in blood levels of creatinine (to monitor your kidney) 
• zvišana koncentracija kreatinina v krvi (za kontrolo ledvic)
Anaphylactic reaction (anaphylaxis) (see section 4.4) 
Bolezni imunskega sistema anafilaktična reakcija (anafilaksija) (glejte poglavje 4.4)
In blister fluids, synovial fluid and peritoneal fluid the tissue/serum ratios ranged from 0.5 to 1. 
V tekočini mehurjev, sinovijski tekočini in peritonealni tekočini je bilo razmerje tkivo/serum od 0,5 do 1.
Fertility Animal reproduction studies have not shown evidence of impairment of fertility. 
Plodnost Študije sposobnosti razmnoževanja pri živalih niso pokazale okvare plodnosti.
However, in the rat, there was an increased incidence of stillbirths at doses of 100 mg/kg/day and above and neonatal mortality at 200 mg/kg/day. 
Vendar pa se je pri podganah pri odmerkih 100 mg/kg/dan in več povečala incidenca mrtvoskotenosti in pri 200 mg/kg/dan neonatalna umrljivost.
How to use Targocid 
Kako uporabljati zdravilo Targocid
Elimination of teicoplanin from peritoneal fluid occurs at the same rate as from serum. 
Iz peritonealne tekočine se teikoplanin odstranjuje enako hitro kot iz seruma.
Teicoplanin is administered by parenteral route (intravenously or intramuscularly). 
Teikoplanin se daje parenteralno (intravensko ali intramuskularno).
Only clear and yellowish solutions should be used. 
Uporabiti se sme le bistro ali rumeno raztopino.
The powder is a spongy ivory coloured homogeneous mass. 
Prašek je gobasta, homogena masa slonokoščene barve.
If you stop having Targocid Do not stop having this medicine without first talking to your doctor, pharmacist or nurse. 
Ne nehajte prejemati tega zdravila, ne da bi se prej posvetovali z zdravnikom, farmacevtom ali medicinsko sestro.
Unchanged form of teicoplanin is the main compound identified in plasma and urine, indicating minimal metabolism. 
Glavna spojina v plazmi in urinu je nespremenjeni teikoplanin; to kaže na minimalno presnovo.
Elimination half-life of teicoplanin varies from 100 to 170 hours in the most recent studies where blood sampling duration is about 8 to 35 days. 
V najnovejših študijah, v katerih je vzorčenje krvi trajalo okrog 8 do 35 dni, je bil eliminacijski razpolovni čas teikoplanina od 100 do 170 ur.